Alumis Inc
ALMS11.400USD
-0.050-0.44%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.19BMarket Cap
LossP/E TTM
More Details of Alumis Inc Company
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Alumis Inc Info
Ticker SymbolALMS
Company nameAlumis Inc
IPO dateJun 28, 2024
CEOBabler (Martin)
Number of employees168
Security typeOrdinary Share
Fiscal year-endJun 28
Address280 East Grand Avenue
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16502316625
Websitehttps://www.alumis.com/
Ticker SymbolALMS
IPO dateJun 28, 2024
CEOBabler (Martin)
Company Executives of Alumis Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Director
Independent Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Roy C. Hardiman, J.D.
Mr. Roy C. Hardiman, J.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Revenue Breakdown
FY2025Q2
FY2025Q1
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
2.67M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ayur Maya Capital Management Company, L.P.
15.57%
Foresite Capital Management, LLC
10.91%
Samsara BioCapital, LLC
5.28%
VenBio Partners LLC
4.75%
The Vanguard Group, Inc.
4.15%
Other
59.33%
Shareholders
Shareholders
Proportion
Ayur Maya Capital Management Company, L.P.
15.57%
Foresite Capital Management, LLC
10.91%
Samsara BioCapital, LLC
5.28%
VenBio Partners LLC
4.75%
The Vanguard Group, Inc.
4.15%
Other
59.33%
Shareholder Types
Shareholders
Proportion
Private Equity
34.56%
Investment Advisor
16.00%
Hedge Fund
11.90%
Investment Advisor/Hedge Fund
9.71%
Venture Capital
8.00%
Research Firm
0.84%
Individual Investor
0.82%
Bank and Trust
0.34%
Pension Fund
0.04%
Other
17.79%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
211
79.11M
81.97%
+900.81K
2025Q3
210
78.21M
82.24%
-347.38K
2025Q2
186
78.54M
55.16%
+26.45M
2025Q1
129
40.48M
86.71%
-471.52K
2024Q4
110
40.33M
76.60%
+5.09M
2024Q3
85
35.23M
67.43%
+3.39M
2024Q2
30
30.28M
0.00%
+30.28M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ayur Maya Capital Management Company, L.P.
15.14M
15.63%
--
--
Jun 30, 2025
Foresite Capital Management, LLC
10.03M
10.35%
-5.17M
-34.02%
Jun 30, 2025
Samsara BioCapital, LLC
4.80M
4.96%
--
--
Jun 30, 2025
VenBio Partners LLC
4.62M
4.77%
+1.83M
+65.74%
Jun 30, 2025
The Vanguard Group, Inc.
3.40M
3.51%
+2.47M
+263.23%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.81M
3.93%
+2.46M
+182.05%
Jun 30, 2025
Trium Capital LLP
2.65M
2.73%
+2.65M
--
Jun 30, 2025
Nextech Invest, Ltd.
2.92M
3.01%
+1.44M
+97.43%
Jun 30, 2025
Cormorant Asset Management, LP
2.15M
2.22%
--
--
Jun 30, 2025
SR One Capital Management, LP
1.96M
2.02%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
iShares Micro-Cap ETF
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Alumis Inc?
The top five shareholders of Alumis Inc are:
Ayur Maya Capital Management Company, L.P. holds 15.14M shares, accounting for 15.63% of the total shares.
Foresite Capital Management, LLC holds 10.03M shares, accounting for 10.35% of the total shares.
Samsara BioCapital, LLC holds 4.80M shares, accounting for 4.96% of the total shares.
VenBio Partners LLC holds 4.62M shares, accounting for 4.77% of the total shares.
The Vanguard Group, Inc. holds 3.40M shares, accounting for 3.51% of the total shares.
Ayur Maya Capital Management Company, L.P. holds 15.14M shares, accounting for 15.63% of the total shares.
Foresite Capital Management, LLC holds 10.03M shares, accounting for 10.35% of the total shares.
Samsara BioCapital, LLC holds 4.80M shares, accounting for 4.96% of the total shares.
VenBio Partners LLC holds 4.62M shares, accounting for 4.77% of the total shares.
The Vanguard Group, Inc. holds 3.40M shares, accounting for 3.51% of the total shares.
What are the top three shareholder types of Alumis Inc?
The top three shareholder types of Alumis Inc are:
Ayur Maya Capital Management Company, L.P.
Foresite Capital Management, LLC
Samsara BioCapital, LLC
Ayur Maya Capital Management Company, L.P.
Foresite Capital Management, LLC
Samsara BioCapital, LLC
How many institutions hold shares of Alumis Inc (ALMS)?
As of 2025Q4, 211 institutions hold shares of Alumis Inc, with a combined market value of approximately 79.11M, accounting for 81.97% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.27%.
What is the biggest source of revenue for Alumis Inc?
In FY2025Q2, the -- business generated the highest revenue for Alumis Inc, amounting to -- and accounting for --% of total revenue.
